Clinical systematic observation of Kangxin capsule curing vascular dementia of senile kidney deficiency and blood stagnation type.
OBJECTIVE
To observe the validity and safety of Kangxin capsule curing the patients with vascular dementia (VaD).


METHODS
Fifty-six patients with vascular dementia of kidney deficiency and blood stagnation type were selected on the basis of defined diagnostic criteria and were randomly divided into Kangxin group (29) and control group (27), observing the relevant accumulation scores in dementia scale before and after treatment and changes of endothelin (ET), sex hormone, immunity and routine examinations.


RESULTS
Kangxin capsule can effectively improve the symptom of patients with VaD of senile kidney deficiency and blood stagnation type, and the average value of curative effect index of 29 patients in the treatment group is 23.01>/=20%, i.e. effective; compared with that before treatment, both CD(4) and CD(4).CD(8)(-1) rises (P<0.05) after the treatment with Kangxin capsule; for the male VaD patients of the Kangxin group, T level increases (P<0.05) and estrodial (E(2)).testerone (T)(-1) value decreases (P<0.05) after the treatment; for the female VaD patients of the Kangxin group, E(2), E(2).T(-1) value increases a great deal (P<0.05) compared with that before treatment; ET level of both groups decreased on average (P<0.01), and did not demonstrate any obvious toxic side effect.


CONCLUSIONS
Kangxin capsule is a valid and safe preparation of Chinese traditional medicine for curing VaD of senile kidney deficiency and blood stagnation type.
Liu
Xifei
X
Department of Neurology, Jinling Hospital, Nanjing, Jiangsu 210002, PR China. xfliu2@yahoo.com.cn
Du
Jian
J
Cai
Jing
J
Liu
Xifeng
X
Xu
Gelin
G
Lin
Anji
A
Teng
Qing
Q
D000368:Aged; D000375:Aging / Q000502:physiology*; D018791:CD4 Lymphocyte Count; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects; D002214:Capsules; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D015140:Dementia, Vascular / Q000175:diagnosis / Q000188:drug therapy*; D004311:Double-Blind Method; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D016232:Endothelins / Q000097:blood; D005260:Female; D012739:Gonadal Steroid Hormones / Q000097:blood; D006402:Hematologic Diseases / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007694:Killer Cells, Natural / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D051437:Renal Insufficiency / Q000175:diagnosis / Q000188:drug therapy*
D002214:Capsules; D002317:Cardiovascular Agents; D004365:Drugs, Chinese Herbal; D016232:Endothelins; D012739:Gonadal Steroid Hormones; C521630:Kangxin